Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplemental Table 1: PBMC subsets that change with treatment

A Classic Subsets	Direction of change	Enzalutamide						
		Pre	d15	p value	d29	p value	d86	p value
NK	↑	6.6	8.8	0.051	9.7	**0.003**	8.2	0.027*
Refined Subsets Changing	Direction of change	Enzalutamide						
		Pre	d15	p value	d29	p value	d86	p value
NK Tim3+	↑	0.53	0.81	0.089	0.90	**0.003**	0.78	0.071
NK Mature	↑	5.53	7.65	0.071	8.68	**0.008**	7.09	0.071
NK Mature Tim3+	↑	0.41	0.68	0.098	0.73	**0.004**	0.68	0.109
MDSCs CD16+	↓	1.19	0.77	0.031*	0.59	0.045*	0.60	**0.008**
MDSCs PDL1+	↓	0.41	0.28	0.263	0.30	**0.020**	0.24	0.035*
gMDSC	↓	0.50	0.21	0.071	0.11	**<0.001**	0.18	**0.002**
gMDSC CD16+	↓	0.46	0.19	**0.015**	0.09	**0.001**	0.13	**0.001**
gMDSC PDL1+	↓	0.28	0.09	0.120	0.06	**0.001**	0.09	0.001*
gMDSC PD1+	↓	0.36	0.17	0.132	0.09	**0.001**	0.15	0.040*
mMDSC	↑	8.63	11.69	0.051	13.06	**0.015**	13.10	**0.031**
B cells PDL1+	↑	0.88	1.11	0.040*	1.26	0.013*	1.22	**<0.001**

B Classic Subsets	Direction of change	Enzalutamide + Vaccine						
		Pre	d15	p value	d29	p value	d86	p value
NK	↑	8.9	11.5	**0.001**	12.3	**0.001**	10.3	0.027*
Refined Subsets Changing	Direction of change	Enzalutamide + Vaccine						
		Pre	d15	p value	d29	p value	d86	p value
CD4+ICOS+	↑	1.77	2.19	**<0.001**	2.16	0.007*	1.52	0.229
CD4+ICOS+PD1+	↑	1.04	1.15	**<0.001**	1.17	0.005*	0.78	0.229
NK Tim3+	↑	1.65	1.90	**<0.001**	2.23	**<0.001**	1.80	**0.009**
NK Mature	↑	7.19	10.10	**0.001**	11.05	**0.001**	8.86	0.043*
NK Mature Tim3+	↑	1.38	1.62	**<0.001**	2.10	**<0.001**	1.57	0.016*

Supplemental Table 1: PBMC subsets that change with treatment. Median frequency of PBMC subsets before and during treatment with Enzalutamide +/- Vaccine. (A) Classic and Refined subsets significantly changing after Enzalutamide alone. (B) Classic and Refined subsets changing after Enzalutamide + Vaccine. Subsets with a potentially biologically relevant change are indicated in bold, and were defined as those with p <0.05, the majority of patients having a >25% change, difference in medians >0.05% of PBMCs, and a frequency >0.1% of total PBMCs. * Although significant p value, majority of patients not changing by >25%.